C. Diff clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • VE303 for Prevention of Recurrent Clostridioides Difficile Infection

    open to eligible people ages 12 years and up

    The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

    Torrance, California and other locations

  • Fecal Microbiota Transplant National Registry

    Sorry, not currently recruiting here

    A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness

    Los Angeles, California and other locations

Our lead scientists for C. Diff research studies include .

Last updated: